Thymidine (Deoxythymidine)
1. Identity, Chemistry, and Natural Sources
Chemical Identity
Thymidine (symbol dT or dThd), also known as deoxythymidine, is a pyrimidine deoxynucleoside. More precisely, it is a pyrimidine 2′-deoxyribonucleoside composed of the nucleobase thymine glycosidically bonded to a 2′-deoxy-β-D-ribofuranose sugar molecule. The chemical formula is C10H14N2O5, with a molar mass of 242.229 g/mol. Chemically, it occurs as a white crystalline powder and is classified as a deoxyribonucleoside due to its deoxyribose sugar.
Thymidine is known under numerous synonyms in the scientific literature, including deoxythymidine, dT, DThyd, Thymidin, 2′-deoxythymidine, 5-methyldeoxyuridine, and 1-(2-deoxy-β-D-ribofuranosyl)-5-methyluracil, among others. The free base of deoxythymidine (thymidine) has the CAS number 50-89-5.
The prefix "deoxy-" is often left out since there are no precursors of thymine nucleotides involved in RNA synthesis. Thymidine occurs almost exclusively in DNA, but it also occurs in the T-loop of transfer RNA (tRNA).
Natural Occurrence and Dietary Sources
Thymidine is found in all living organisms as a structural component of DNA. Nucleosides such as thymidine can be produced by de novo synthesis pathways in the liver; they may also be obtained from the diet. When the diet contains nucleotides, the body digests them by nucleotidases to produce nucleosides and phosphates; nucleosides are then degraded into their subcomponents (nucleobases and sugar) by the action of nucleosidases in the lumen of the digestive tract. Some of the dietary sources of thymidine are DNA-enriched foods such as fish, beans, and legumes.
Industrially, thymidine has historically been produced by the hydrolysis of DNA derived from natural sources, such as milt (fish sperm). Before the boom in thymidine use caused by the need for thymidine in the production of the antiretroviral drug azidothymidine (AZT), much of the world's thymidine production came from herring sperm. A newer approach involves production of thymidine by the transfer of the 2′-deoxyribose moiety of 2′-deoxyinosine to thymine, catalyzed by the transdeoxy-glycosylation activity of Bacillus stearothermophilus.
Common Forms and Preparations
Thymidine is commercially available in several forms relevant to both research and potential therapeutic use:
- Free nucleoside (thymidine / deoxythymidine): The unmodified nucleoside, used in cell biology, research, and as a precursor for pharmaceutical synthesis.
- Thymidine monophosphate (dTMP): Thymidine monophosphate (TMP) is a nucleotide formed by all microorganisms during DNA production. It is used in clinical contexts, particularly for mitochondrial disease therapy.
- Thymidine triphosphate (dTTP): The fully phosphorylated, polymerization-ready form incorporated into DNA.
- Radiolabeled thymidine (³H-thymidine): Methods of labelling have progressed from radiolabel-detection using ³H-thymidine to other imaging-based detection methods which utilize antibodies and/or chemical-based approaches to detect incorporated nucleosides.
- Thymidine analogues: Some antiviral drugs, especially those targeting retroviruses such as HIV, are thymidine analogs. For example, zidovudine (AZT) is a thymidine analog that can be mistakenly used by viral reverse transcriptase to synthesize DNA, thereby interrupting the viral replication process. Telbivudine (β-L-2′-deoxythymidine, LdT) is the unmodified "unnatural" L-enantiomer of thymidine that was used in the treatment of chronic hepatitis B.
2. Historical and Traditional Use
Biochemical Research Context
Thymidine does not carry a history of use in traditional herbal or folk medicine systems. It is not a botanical ingredient with ethnobotanical traditions. Its significance emerged entirely from twentieth-century molecular biology and biochemistry. Thymidine's significance was underscored in foundational studies on DNA structure and function, with researchers utilizing radiolabeled thymidine to trace cell proliferation and genetic processes.
The use of tritium-labeled thymidine (³H-thymidine) as a tracer to study DNA replication and cell division was a pivotal methodological advance in cell biology and cancer research from the 1950s onward. Thymidine (TdR) was used to study the kinetics of in vitro cell proliferation and was subsequently used clinically as a single agent at high doses.
Early Clinical Investigations (1970s–1980s)
The first formal clinical uses of exogenous thymidine occurred in the context of oncology. Beginning in the late 1970s, thymidine was investigated both as a direct antitumor agent (exploiting its ability to arrest dividing cells) and as a biochemical modulator designed to enhance the efficacy and reduce the toxicity of established cytotoxic drugs. Clinical trials were initiated with TdR alone, TdR combined with methotrexate (MTX), and TdR combined with 5-fluorouracil (FU). Metabolic modulation with metabolites such as uridine (UR) and a hormone (testosterone) was demonstrated to protect from host toxicity due to certain anticancer agents without offsetting antitumor activity; the ability to prevent leukopenia by these means was particularly impressive.
3. Key Constituents, Biochemistry, and Mechanisms of Action
Structural Role in DNA
Thymidine, a deoxyribonucleoside, is incorporated into DNA through a series of enzymatic phosphorylations that activate it for polymerization. Deoxythymidine is the DNA nucleoside T, which pairs with deoxyadenosine (A) in double-stranded DNA. This base-pairing occurs through two hydrogen bonds and is essential for maintaining the fidelity and stability of the genome.
De Novo vs. Salvage Pathways for Thymidylate Biosynthesis
There are two fundamentally distinct routes by which cells acquire thymidylate (thymidine nucleotides):
De novo synthesis: The de novo pathway involves the conversion of deoxyuridine monophosphate (dUMP) to thymidylate (dTMP), catalyzed by the tetrahydrofolate (THF)-dependent enzymes serine hydroxymethyltransferase (SHMT), thymidylate synthase (TYMS), and dihydrofolate reductase (DHFR). In this pathway, 5,10-methyleneTHF, a one-carbon donor, is generated from serine by SHMT and used for the conversion of dUMP to dTMP in a reaction catalyzed by TYMS. De novo thymidylate biosynthesis can occur in the cytosol and nucleus; nuclear synthesis enables the generation of dTMP at the site of DNA replication. During cell division, the cytosolic enzymes constituting the thymidylate cycle (SHMT1, TYMS, DHFR, and MTHFD1) are translocated to the nucleus following their modification by small ubiquitin-like modifier proteins.
Salvage pathway: In thymidine salvage, thymidine is transported across the cell membrane and phosphorylated by TK1 into thymidine monophosphate (TMP); this TMP is further phosphorylated into thymidine diphosphate (TDP) and thymidine triphosphate (TTP), which is then incorporated into DNA. The flux through both the exogenous (salvage) and endogenous (de novo) pathways is ultimately controlled by the rate of DNA synthesis, with thymidine kinase regulating the salvage pathway.
Mitochondrial synthesis: The salvage pathway also occurs in the mitochondria, catalyzed by TK2 (thymidine kinase 2) and thymidine kinase 1 (TK1) in the cytoplasm, respectively. De novo thymidylate synthesis in mitochondria prevents uracil accumulation in mitochondrial DNA (mtDNA); these data indicate that, unlike other nucleotides, de novo dTMP synthesis occurs within mitochondria and is essential for mtDNA integrity.
Nucleotide pool balance and genome stability: De novo thymidylate biosynthesis is impaired by folate or vitamin B12 deficiency. Impaired de novo thymidylate biosynthesis causes uracil misincorporation into DNA and DNA instability. Tetrahydrofolates (THF) are a family of cofactors that carry and chemically activate one-carbon units for the de novo synthesis of guanosine, adenosine, and thymidine nucleotides, and for the remethylation of homocysteine to methionine.
Cell Cycle Arrest at the G1/S Boundary
At supraphysiological concentrations, exogenous thymidine disrupts normal dNTP pool ratios. Thymidine is a DNA synthesis inhibitor that can arrest cells at the G1/S boundary, prior to DNA replication. Thymidine is useful in cell synchronization during S-phase. This property underpins the "double thymidine block," a widely used laboratory technique, as well as the rationale for earlier clinical applications of high-dose thymidine in cancer treatment.
Thymidine Phosphorylase and Catabolism
Thymidine phosphorylase (TP), encoded by TYMP, is a cytosolic enzyme that catalyzes the conversion of thymidine to thymine and deoxyuridine to uracil, and is therefore essential for the nucleotide salvage pathway. Proper activity of thymidine phosphorylase is critical to maintaining physiologically appropriate levels of circulating thymidine; enzymatic deficiency leads to pathological nucleoside accumulation (see MNGIE, below).
Thymidine Kinase (TK1) as a Proliferation Marker
Thymidine Kinase (TK) is a cell-cycle regulated enzyme essential to DNA synthesis and a marker of cell proliferation and tumor aggressiveness. TK is released into the bloodstream, and measurement of its activity (TKa) serves as a predictive and dynamic biomarker providing valuable insights in drug development. In malignant cells, TK1 expression levels are upregulated and the enzyme seems to lose its normal cell-cycle regulation control elements; as cancer progresses, TK1 activity levels increase in tissues and in serum proportionally to tumor size and stage of disease.
4. Scientific Evidence by Area of Use
4.1 Mitochondrial DNA Depletion Syndromes — Thymidine Kinase 2 (TK2) Deficiency
This represents the most clinically advanced area of thymidine-based therapeutic use. Thymidine kinase 2, encoded by the nuclear gene TK2, is required for mitochondrial DNA maintenance; autosomal recessive TK2 mutations cause depletion and multiple deletions of mtDNA that manifest predominantly as a myopathy usually beginning in childhood and progressing relentlessly.
Treatment with pyrimidine deoxynucleosides — deoxycytidine and thymidine — ameliorates mitochondrial defects and extends the lifespan of Tk2 knock-in mice (Tk2KI); compassionate-use deoxynucleoside therapy in TK2-deficient patients has shown promising indications of efficacy.
Clinical evidence: In a compassionate-use program, deoxynucleoside monophosphates and deoxynucleosides were administered to 16 TK2-deficient patients. In 5 patients with early onset and severe disease, survival and motor functions were better than in historically untreated patients; in 11 childhood and adult onset patients, clinical measures stabilized or improved. Three of 8 patients who were nonambulatory at baseline gained the ability to walk on therapy; 4 of 5 patients who required enteric nutrition were able to discontinue feeding tube use; and 1 of 9 patients who required mechanical ventilation became able to breathe independently.
Preclinical support: Deoxycytidine monophosphate and deoxythymidine monophosphate (dCMP/dTMP) supplementation was described as the first effective pharmacologic treatment for Tk2 deficiency in murine models. For mtDNA depletion syndromes, particularly in thymidine kinase 2 deficiency, supplementation with deoxythymidine and deoxycytidine monophosphates or their deoxynucleosides shows promise in delaying the onset of molecular and biochemical abnormalities and prolonging life in cellular and murine models.
Evidence strength: Preclinical evidence (mouse models, cell culture) is strong. Clinical evidence derives from a small, uncontrolled compassionate-use cohort (n=16) without randomization or placebo control, limiting interpretability. This area is nonetheless among the most therapeutically promising for direct thymidine (deoxynucleoside) administration.
4.2 Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) — Thymidine Excess
In contrast to TK2 deficiency (where thymidine supplementation is therapeutic), MNGIE illustrates the toxicity of pathologically elevated thymidine. MNGIE-MTDPS1 is a devastating autosomal recessive disorder due to mutations in TYMP, which cause a loss of function of thymidine phosphorylase (TP), nucleoside accumulation in plasma and tissues, and mitochondrial dysfunction. Thymidine and deoxyuridine accumulate, impairing mitochondrial DNA maintenance and integrity; clinically, patients show severe and progressive gastrointestinal and neurological manifestations, with onset typically in the second decade of life and a mean age at death of 37 years.
MNGIE is an autosomal recessive disease due to ECGF1 gene mutations causing thymidine phosphorylase (TP) deficiency; analysis of post-mortem samples of MNGIE patients revealed TP activity in all control tissues but not in MNGIE samples, and thymidine and deoxyuridine were absent in control samples but present in all tissues of MNGIE patients.
Therapeutic approaches in MNGIE focus on reducing the toxic nucleoside excess. Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) was well tolerated, and reductions in disease-associated plasma metabolites thymidine and deoxyuridine were observed in all three patients studied; clinical improvements, including weight gain and improved disease scores, were observed in two patients.
Evidence strength: Mechanistic evidence for the role of thymidine accumulation in MNGIE pathology is well-established at the biochemical and genetic levels. Clinical trial data for EE-TP are limited to very small open-label studies due to disease rarity. Currently, there are no treatments for MNGIE where effectiveness has been evidenced in large clinical trials.
4.3 High-Dose Thymidine in Cancer Treatment (Historical Clinical Trials)
During the 1970s and 1980s, thymidine was investigated as a direct anticancer agent and as a modulator of fluoropyrimidine chemotherapy. This work represents the largest body of human clinical data for exogenous thymidine administration.
Direct cytotoxic use: The physiological pyrimidine nucleoside thymidine (dThd) is cytotoxic to normal and neoplastic cells in culture that are exposed to concentrations in excess of 1 mM for prolonged periods. To explore the antileukemic potential, six patients with relapsed leukemia or lymphoma were treated by prolonged infusions of dThd at dosages of 90 to 240 g/m²/day for 14 to 29 days; mean plasma dThd concentration ranged from 3.8 to 5.5 mM. In five patients, the proportion of cells in S phase increased during the first few days of the infusion but then returned to baseline concomitant with an overall reduction in bone marrow blasts; the magnitude of tumor cell kill ranged from 0.7 to 3.6 logs of blasts/mm³ of bone marrow, and the data demonstrated that dThd was able to induce a complete remission in a patient with acute leukemia previously refractory to treatment.
Combination with 5-fluorouracil (5-FU): Phase I observations of combined therapy with thymidine (TdR) and 5-fluorouracil (FU) demonstrated that when TdR is administered by rapid infusion at a dose of 7.5 or 15 g and FU is given by bolus injection 60 minutes after the start of the TdR dose, the biologic activity of FU is increased five- to eight-fold. The effects of thymidine coadministration on the pharmacokinetics and metabolism of 5-FU were investigated in 29 colorectal cancer patients; five patients received 5-day IV infusion of FU at 15 mg/kg/day, and 24 patients received infusion of FU (7.5 mg/kg/day, 5 days) and dThd (216 mg/kg/day, 6 days) preceded by a bolus dose of dThd (405 mg/kg). Concurrent dThd administration reduced the plasma clearance of FU at steady state from 389.1 ± 153.5 to 56.0 ± 36.4 liters/kg/day; the mean steady-state plasma concentration of FUra in patients receiving FUra alone was 0.38 µM, significantly lower than the 1.30 µM in patients receiving the FUra-dThd combination.
However, the clinical benefit of this combination for tumor response was not confirmed: concurrent IV administration of 5-FU and TdR did not improve the response rate over that obtained with 5-FU alone.
Evidence strength: These studies demonstrated clear pharmacological effects of high-dose exogenous thymidine in humans but failed to demonstrate a superior clinical outcome for the thymidine+5-FU combination versus 5-FU alone. The clinical investigation of thymidine as a direct oncology agent was largely discontinued due to the very large drug quantities required, fluid volumes, and prolonged infusion durations needed to achieve cytoreduction, coupled with significant toxicity.
4.4 DNA Synthesis and Cell Proliferation Research
Thymidine's most established, reproducible utility in human biology is as a laboratory tool. In cell biology, thymidine is used to synchronize cells in the G1/early S phase. Cell synchronization is widely used for studying mechanisms of cell cycle progression regulation; thymidine is a DNA synthesis inhibitor that can arrest cells at the G1/S boundary, prior to DNA replication. The "double thymidine block" — sequential treatment and release — is a standard experimental protocol for cell cycle studies.
Among the most common approaches to obtain populations of synchronized cells, particularly in S-phase, is cell synchronization using DNA replication inhibitors including high concentrations of thymidine. However, inhibitors of DNA replication such as thymidine were shown to induce phosphorylation of histone H2AX on Ser-139, indicating that high-dose thymidine block induces a measurable DNA damage response signal, which is a limitation for certain research applications.
4.5 Stem Cell Therapy Research
Emerging research has investigated thymidine supplementation as a control mechanism for stem cell-derived therapies. A genetic modification in stem cells can make their proliferation possible only under thymidine supplementation; this method is proposed to reduce the risk of uncontrolled cell proliferation for stem cell-based therapies. Results from experimental studies suggest that supplementation with exogenous thymidine affects stem cell proliferation, but not the function of stem cell-derived cells. This field remains in preclinical stages of development.
4.6 Thymidylate Cycle, Folate Status, and Neural Tube Defects
The enzymes responsible for de novo dTMP synthesis comprise the thymidylate cycle. Thymidylate synthase converts deoxyuridylate and the folate cofactor 5,10-methylenetetrahydrofolate (5,10-methyleneTHF) to dTMP and dihydrofolate (DHF); DHF is converted to tetrahydrofolate (THF) by DHF reductase, which is then recycled back to 5,10-methyleneTHF by serine hydroxymethyltransferase (SHMT) using serine as a one-carbon source. Perturbations to this cycle, driven by folate or B12 inadequacy, affect thymidylate availability and have been linked to neural tube defects in animal models; dietary deoxyuridine and uridine have been shown to have opposing effects on neural tube defect incidence in animal models mediated by changes in de novo thymidylate biosynthesis, though direct human intervention data with thymidine itself in this context are not established.
5. Body Systems and Health Areas of Association
Genome Integrity and DNA Replication
The central role of thymidine is ensuring the faithful replication of DNA. Thymidylate biosynthesis in the nucleus functions during DNA replication and repair. The enzymes that comprise the dTMP cycle have been shown to form a multienzyme complex that colocalizes with the DNA replication machinery, such that dTMP is synthesized at sites of DNA synthesis.
Mitochondrial Biology
Thymidine kinase 2 (TK2), a ubiquitously expressed enzyme critical for the salvage pathways for pyrimidine within mitochondria, phosphorylates both deoxycytidine (dC) and deoxythymidine (dT); those deoxynucleoside monophosphates are subsequently phosphorylated to dCTP and dTTP, which are vital building blocks for replication and maintenance of mitochondrial DNA particularly in post-mitotic cells.
Hematopoietic and Immune System
Rapidly dividing hematopoietic cells (bone marrow, peripheral blood cells) are highly sensitive to perturbations in dNTP pools. At serum TdR levels of 10⁻³ M, TdR exposure for greater than 24 hours resulted in bone marrow hypocellularity and peripheral myelosuppression; pathologic findings were also noted in the intestinal mucosa. The hematopoietic system is consequently a primary target of both therapeutic and toxic effects of high-dose thymidine.
Oncology / Cell Proliferation
During the last three decades, scientific evidence has shown that TK1 levels in the serum of cancer patients can be used as a biomarker for early cancer detection; TK1 levels in serum are correlated with tumor progression, patient response, and cancer recurrence, making TK1 a suitable tumor biomarker for continued monitoring of patients. Thymidylate synthesis enzymes have been successfully targeted by chemotherapeutic agents for treatment of several types of cancers; common polymorphisms in the TYMS gene are associated with cancer risk.
Gastrointestinal and Neuromuscular Systems (in Disease States)
In MNGIE, pathological thymidine accumulation due to thymidine phosphorylase deficiency causes progressive gastrointestinal dysmotility, cachexia, ptosis and ophthalmoparesis, peripheral neuropathy, and diffuse leukoencephalopathy, which usually lead to death in early adulthood. This illustrates how aberrant thymidine homeostasis directly damages both the gastrointestinal and central and peripheral nervous systems.
6. Dosage Forms and Reported Dosages
Thymidine is not currently approved as a dietary supplement with established reference intake values by regulatory agencies such as the U.S. FDA, EFSA, or WHO. The dosages below reflect those reported in peer-reviewed clinical and preclinical research.
- High-dose intravenous infusion (historical oncology trials):
Each 6-day treatment course consisted of an IV loading dose of TdR (405 mg/kg, over 30 min), followed by continuous IV infusions of 5-FU (7.5 mg/kg per day for 5 days) and TdR (216 mg/kg per day for 6 days); courses were repeated every 4 weeks.
- Very high-dose infusion for leukemia/lymphoma:
Patients with relapsed leukemia or lymphoma were treated with prolonged infusions of dThd at dosages of 90 to 240 g/m²/day for 14 to 29 days, with mean plasma dThd concentrations ranging from 3.8 to 5.5 mM.
- Phase I oncology combination (TdR + 5-FU):
When TdR was administered by rapid infusion at a dose of 7.5 or 15 g and FU was given by bolus injection 60 minutes after the start of the TdR dose, the biologic activity of FU was increased five- to eight-fold.
- TK2 deficiency (compassionate use — deoxynucleosides including thymidine):
Deoxynucleoside monophosphate and deoxynucleoside therapies were administered to 16 TK2-deficient patients under a compassionate-use program. Specific mg/kg doses for these protocols have been described in the primary literature from the Hirano group, though exact regimens are reported as variable based on patient age and disease severity.
- In vitro cell synchronization:
Serum TdR levels of 10⁻⁴ M were sufficient to induce arrest of cell growth in S phase by inhibition of DNA synthesis in animal model experiments, providing a mechanistic reference point for biological activity thresholds.
No standard oral supplemental dosage for thymidine in healthy humans has been established in the peer-reviewed literature. Despite its promising biological roles, direct clinical evidence supporting the benefits of thymidine supplementation in healthy individuals is currently limited; most human research has focused on its use as a diagnostic or experimental tool rather than as a nutritional supplement.
7. Safety, Toxicity, and Drug Interactions
Dose-Dependent Toxicity in Animal Models
The pharmacologic effects and plasma concentrations produced by high-dose intraperitoneal administration of thymidine were determined in CDF1 mice. Within 15 minutes after injection at a dose of 4.075 g/kg (between LD0 and LD50), mean arterial blood pressure and heart rate fell precipitously and remained depressed for over 6 hours; sedation and anuresis were consistently observed.
In vivo cytokinetic effects of TdR on rapidly proliferating cell populations were explored by continuous infusions in rats; at levels of 10⁻³ M, TdR exposure for greater than 24 hours resulted in bone marrow hypocellularity and peripheral myelosuppression; pathologic findings were also noted in the intestinal mucosa. The nucleoside was lethal at high doses when serum levels approached 10⁻² M.
Clinical Toxicity in Human Studies
In patients receiving very high-dose intravenous thymidine for leukemia/lymphoma, the reported side effects included nausea and vomiting in all patients, hepatotoxicity in two patients, electrolyte imbalance in one, progression of a pericardial effusion to tamponade in one, and mild central nervous system toxicity in five. Diarrhea was dose-limiting in one patient.
In trials combining thymidine with 5-FU: Myelotoxicity occurred in 64% of patients but was dose-limiting in only 20%; gastrointestinal and neurological symptoms were mild and infrequent; there was one case of treatment-related death due to sepsis secondary to leukopenia.
The observed toxicity from TdR + 5-FU combinations was primarily hematopoietic: at 15 g TdR and 7.5 or 10 mg/kg FU, median white blood count nadirs of 2,600 on day 16 and platelet count nadirs of 150,000 on day 14 were recorded.
Pathological Thymidine Accumulation
Evidence from MNGIE — an inborn error of thymidine catabolism — demonstrates that chronically elevated circulating thymidine is itself pathogenic. The lack of thymidine phosphorylase results in systemic accumulation of deoxyribonucleosides thymidine (dThd) and deoxyuridine (dUrd); in these patients, clinical features include mental regression, ophthalmoplegia, and fatal gastrointestinal complications; the accumulation of nucleosides also causes imbalances in mitochondrial DNA deoxyribonucleoside triphosphates (dNTPs), which may play a direct or indirect role in mtDNA depletion/deletion abnormalities.
Drug Interactions
Antiretroviral drugs (nucleoside/nucleotide reverse transcriptase inhibitors, NRTIs): Stavudine (a thymidine analog) led to a moderate but significant decrease in mtDNA copy number. Antiretrovirals that are thymidine analogs (e.g., stavudine, zidovudine) compete with natural thymidine for phosphorylation by thymidine kinase and incorporation into DNA, meaning co-administration of exogenous thymidine could theoretically modulate NRTI efficacy or toxicity, though controlled human data in this specific context are limited.
5-Fluorouracil (5-FU): As described in clinical trials above, thymidine pharmacokinetically interacts with 5-FU. Concurrent dThd administration significantly reduced the plasma clearance of FU at steady state. This interaction substantially alters 5-FU exposure and its toxicity profile.
Methotrexate (MTX) and antifolates: Because of the similarity to dihydrofolic acid, methotrexate inhibits dihydrofolate reductase, thus inhibiting the biosynthesis of thymidine and thereby reduces its content within cells. Conversely, exogenous thymidine can bypass the thymidylate synthesis blockade imposed by antifolates, reducing antifolate efficacy in both therapeutic and laboratory settings.
DNA damage response inducers: Thymidine (at high concentrations used for cell synchronization) was shown to induce phosphorylation of histone H2AX on Ser-139, a marker of DNA double-strand breaks. This suggests that supraphysiological thymidine concentrations engage DNA damage response pathways in dividing cells.
Mutation rate effects: During growth of bacteriophage T4, both an excess and a deficiency of thymidine availability increases mutation frequency, illustrating that deviations from normal thymidine homeostasis in either direction can compromise replication fidelity.
Summary of Evidence Limitations
The great majority of data on thymidine pharmacology in humans derives from high-dose intravenous administration in the clinical contexts of oncology or rare mitochondrial disease — conditions that are not analogous to standard dietary supplementation. Physiological dietary exposure to thymidine (through normal food consumption of DNA-rich foods) has not been separately characterized in controlled human studies with respect to health outcomes. There are no established reference intakes, tolerable upper limits, or regulatory approvals for thymidine as a standalone dietary supplement from any major health authority reviewed.
References
Go back